Cargando…

GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway

BACKGROUND: Endothelial-to-mesenchymal transition (EndMT) is a pathophysiological change in the vascular endothelium commonly seen in the cardiovascular system. Elevated serum Growth differiention factor 15 (GDF15) has been reported in VTE patients, but the relationship and mechanism between GDF15,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yeping, Zhu, Huiqi, Xin, Wanghao, Wang, Jiaoyan, Yan, Chao, Ying, Kejing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506185/
https://www.ncbi.nlm.nih.gov/pubmed/37723495
http://dx.doi.org/10.1186/s12959-023-00547-7
_version_ 1785107066490191872
author Li, Yeping
Zhu, Huiqi
Xin, Wanghao
Wang, Jiaoyan
Yan, Chao
Ying, Kejing
author_facet Li, Yeping
Zhu, Huiqi
Xin, Wanghao
Wang, Jiaoyan
Yan, Chao
Ying, Kejing
author_sort Li, Yeping
collection PubMed
description BACKGROUND: Endothelial-to-mesenchymal transition (EndMT) is a pathophysiological change in the vascular endothelium commonly seen in the cardiovascular system. Elevated serum Growth differiention factor 15 (GDF15) has been reported in VTE patients, but the relationship and mechanism between GDF15, EndMT and VTE are still unclear. METHODS: We performed a retrospective clinical study, and human serum GDF15 expression levels were detected. The mouse DVT model was established through subtotal ligation of the mouse inferior vena cava, and then we detected intimal changes and thrombi in the stenotic inferior vena cava by haematoxylin-eosin (HE) staining, Masson staining, and Sirius Red staining. The expression levels of GDF15 and SM22 were detected by immunohistochemistry and RT‒qPCR. Serum samples of mice were collected, and the expression level of GDF15 in serum was detected. Human umbilical vein endothelial cells (HUVECs) were stimulated with a cytokine mixture (TGF-β1 + TNF-α + IL-1β). The role and mechanism of GDF15 in EndMT and VTE were detected in HUVECs and in a DVT mice model. RESULTS: We found that serum GDF15 levels in both VTE patients and mouse DVT models were higher than those in the control group. EndMT was increased in the stenotic vascular tissue of mice. Further experiments showed that GDF15 could promote the EndMT of HUVECs and reduce their anticoagulation and antifibrinolytic ability through the smad2/p-smad2/snail pathway. Inhibition of mature GDF15 release can significantly reduce venous thrombotic fibre deposition in mice. CONCLUSIONS: GDF15 positively promotes EndMT through activation of the Smad2/psmad2/snail pathway, and inhibition of GDF15 expression can alleviate the EndMT process, further improving the coagulation and fibrinolytic function of endothelial cells and thus reducing the local fibre deposition of venous thrombi. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00547-7.
format Online
Article
Text
id pubmed-10506185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105061852023-09-19 GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway Li, Yeping Zhu, Huiqi Xin, Wanghao Wang, Jiaoyan Yan, Chao Ying, Kejing Thromb J Research BACKGROUND: Endothelial-to-mesenchymal transition (EndMT) is a pathophysiological change in the vascular endothelium commonly seen in the cardiovascular system. Elevated serum Growth differiention factor 15 (GDF15) has been reported in VTE patients, but the relationship and mechanism between GDF15, EndMT and VTE are still unclear. METHODS: We performed a retrospective clinical study, and human serum GDF15 expression levels were detected. The mouse DVT model was established through subtotal ligation of the mouse inferior vena cava, and then we detected intimal changes and thrombi in the stenotic inferior vena cava by haematoxylin-eosin (HE) staining, Masson staining, and Sirius Red staining. The expression levels of GDF15 and SM22 were detected by immunohistochemistry and RT‒qPCR. Serum samples of mice were collected, and the expression level of GDF15 in serum was detected. Human umbilical vein endothelial cells (HUVECs) were stimulated with a cytokine mixture (TGF-β1 + TNF-α + IL-1β). The role and mechanism of GDF15 in EndMT and VTE were detected in HUVECs and in a DVT mice model. RESULTS: We found that serum GDF15 levels in both VTE patients and mouse DVT models were higher than those in the control group. EndMT was increased in the stenotic vascular tissue of mice. Further experiments showed that GDF15 could promote the EndMT of HUVECs and reduce their anticoagulation and antifibrinolytic ability through the smad2/p-smad2/snail pathway. Inhibition of mature GDF15 release can significantly reduce venous thrombotic fibre deposition in mice. CONCLUSIONS: GDF15 positively promotes EndMT through activation of the Smad2/psmad2/snail pathway, and inhibition of GDF15 expression can alleviate the EndMT process, further improving the coagulation and fibrinolytic function of endothelial cells and thus reducing the local fibre deposition of venous thrombi. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00547-7. BioMed Central 2023-09-18 /pmc/articles/PMC10506185/ /pubmed/37723495 http://dx.doi.org/10.1186/s12959-023-00547-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Yeping
Zhu, Huiqi
Xin, Wanghao
Wang, Jiaoyan
Yan, Chao
Ying, Kejing
GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title_full GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title_fullStr GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title_full_unstemmed GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title_short GDF15 affects venous thrombosis by promoting EndMT through smad2/p-smad2 pathway
title_sort gdf15 affects venous thrombosis by promoting endmt through smad2/p-smad2 pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506185/
https://www.ncbi.nlm.nih.gov/pubmed/37723495
http://dx.doi.org/10.1186/s12959-023-00547-7
work_keys_str_mv AT liyeping gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway
AT zhuhuiqi gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway
AT xinwanghao gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway
AT wangjiaoyan gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway
AT yanchao gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway
AT yingkejing gdf15affectsvenousthrombosisbypromotingendmtthroughsmad2psmad2pathway